UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S396-S397

2021

Volltextzugriff (PDF)

Letter: immunogenicity of infliximab originator vs. CT‐P13 in IBD patients

Alimentary pharmacology & therapeutics, 2017-11, Vol.46 (9), p.903-905

2017

Volltextzugriff (PDF)

Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits

Pathology, 2017-04, Vol.49 (3), p.332-334

2017

Volltextzugriff (PDF)

FRI0212 Comparison Study of Tests Available To Monitor Tocilizumab Therapy in Rheumatic Patients

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.508-508

2016

Volltextzugriff (PDF)

AB0656 Clinical Relevance of Measuring Free versus Total Anti-Infliximab Antibodies in Patients with Spondyloarthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1128-1129

2016

Volltextzugriff (PDF)

OP0015 Antibodies To Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity towards Biosimilar CT-P13

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.58-58

2016

Volltextzugriff (PDF)

SAT0125 Association of Rituximab Levels to Clinical Response and B Cell Recovery in Rheumatoid Arthritis Patients

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A623-A623

2013

Volltextzugriff (PDF)

AB0370 COMPARISON OF A NEW RANDOM-ACCESS SOLUTION FOR THERAPEUTIC DRUG MONITORING OF ADALIMUMAB TO THE REFERENCE ELISA TEST

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1312-1312

2022

Volltextzugriff (PDF)

AB0354 THERAPEUTIC DRUG MONITORING: PERFORMANCE OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST FOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGER PRICK

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1303-1303

2022

Volltextzugriff (PDF)

AB0356 THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1304-1305

2022

Volltextzugriff (PDF)

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Rheumatology (Oxford, England), 2011-08, Vol.50 (8), p.1445-1452

2011

Volltextzugriff (PDF)

Comparison of percutaneous tracheostomy methods in intensive care patients: blind, fibreoptic bronchoscopy and fibreoptic bronchoscopy plus ultrasound

British journal of anaesthesia : BJA, 2018-07, Vol.121 (1), p.e12-e13

2018

Volltextzugriff (PDF)

Evaluation of antiasthmatic activity of Cassia sophera linn

Pharmacognosy Magazine, 2009-07, Vol.5 (19), p.109

2009

Volltextzugriff (PDF)

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i353-i354

2022

Volltextzugriff (PDF)

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1580-i1580

2024

Volltextzugriff (PDF)

AB0369 CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1311-1312

2022

Volltextzugriff (PDF)

P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S265-S266

2019

Volltextzugriff (PDF)

P431 Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S324-S324

2019

Volltextzugriff (PDF)

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S299-S299

2018

Volltextzugriff (PDF)

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S366-S366

2021

Volltextzugriff (PDF)

P554 Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S391-S391

2019

Volltextzugriff (PDF)

PTU-087 Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases

Gut, 2015-06, Vol.64 (Suppl 1), p.A99-A99

2015

Volltextzugriff (PDF)

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S387-S387

2019

Volltextzugriff (PDF)

SAT0150 Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases: preliminary results of ingebio study

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.826

2017

Volltextzugriff (PDF)

PrP polymorphisms in Basque sheep breeds determined by PCR-restriction fragment length polymorphism and real-time PCR

Veterinary record, 2004-06, Vol.154 (23), p.717-722

2004

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

ThemaAdolescent

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(80)
Berichte
(1)

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

Letter: immunogenicity of infliximab originator vs. CT‐P13 in IBD patients

Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits

FRI0212 Comparison Study of Tests Available To Monitor Tocilizumab Therapy in Rheumatic Patients

AB0656 Clinical Relevance of Measuring Free versus Total Anti-Infliximab Antibodies in Patients with Spondyloarthritis

OP0015 Antibodies To Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity towards Biosimilar CT-P13

SAT0125 Association of Rituximab Levels to Clinical Response and B Cell Recovery in Rheumatoid Arthritis Patients

AB0370 COMPARISON OF A NEW RANDOM-ACCESS SOLUTION FOR THERAPEUTIC DRUG MONITORING OF ADALIMUMAB TO THE REFERENCE ELISA TEST

AB0354 THERAPEUTIC DRUG MONITORING: PERFORMANCE OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST FOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGER PRICK

AB0356 THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Comparison of percutaneous tracheostomy methods in intensive care patients: blind, fibreoptic bronchoscopy and fibreoptic bronchoscopy plus ultrasound

Evaluation of antiasthmatic activity of Cassia sophera linn

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

AB0369 CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE

P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

P431 Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

P554 Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA

PTU-087 Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

SAT0150 Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases: preliminary results of ingebio study

PrP polymorphisms in Basque sheep breeds determined by PCR-restriction fragment length polymorphism and real-time PCR

Aktive Filter

Suchergebnisse filtern